Marzia Del Re
0000-0001-7343-6161
Universita' di Pisa
100 papers found
Refreshing results…
Biosimilars in oncology. Focus on SB3 studies,Biosimilari in oncologia. SB3: Dagli studi preclinici agli studi clinici
Genome Wide Association Studies (GWAS)
Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy
Implications of KRAS mutations in acquired resistance to treatment in NSCLC
DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer
Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment
Early changes in plasma levels of mutant KRAS DNA as a sensitive marker of response to chemotherapy in pancreatic cancer
Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment
Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer
Critical focus on mechanisms of resistance and toxicity of m-TOR inhibitors in pancreatic neuroendocrine tumors
Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life
Pharmacogenetics and Metabolism from Science to Implementation in Clinical Practice: The Example of Dihydropyrimidine Dehydrogenase
The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients
The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide
Determinants of bone specific metastasis in prostate cancer
Unusual gastrointestinal and cutaneous toxicities by bleomycin, etoposide, and cisplatin: a case report with pharmacogenetic analysis to personalize treatment
IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients
Should CYP2D6 be genotyped when treating with tamoxifen? [Letter in reply]
Should CYP2D6 be genotyped when treating with tamoxifen?
Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins
Missing publications? Search for publications with a matching author name.